chronic%20myeloid%20leukemia
CHRONIC MYELOID LEUKEMIA

Chronic myelogenous leukemia (CML) is a malignant myeloid disorder characterized by the presence of a distinctive cytogenetic abnormality known as the Philadelphia chromosome.

Exposure to ionizing radiation is the only known risk factor with median presentation at age >50 years old.

Three phases of the disorder are chronic, accelerated and blast.

Choice of therapy is influenced by age, availability of a donor, comorbidities and phase of CML.

Chronic Myeloid Leukemia Drug Information

Drug Information

Indication: In combination w/ cyclophosphamide as conditioning regimen prior to allogeneic hematopoietic progenitor cell t...

Indication: Induction & maintenance of remission in acute myelocytic leukaemia in adult & childn. Other leukemias ...

Indication: Alone or in combination w/ other chemotherapeutic agents for induction of remission of acute myeloid leukaemia...

Indication: Adult patients suffering from Philadelphia-positive (Ph+) chronic myeloid leukaemia (CP, AP or BP) or Ph+ acut...

Indication: Chronic granulocytic leukaemia. Prolongs remission in polycythaemia vera, particularly in cases w/ marked thro...

1  /  2
Editor's Recommendations
Most Read Articles
31 Mar 2021
At the recent webinar entitled Pik Me Up: Mutation Matters, Consultant Medical Oncologist Dr Senthil Rajappa discussed the role of PI3Kα-specific inhibitor alpelisib (TREZILENT®, Novartis) in managing patients with HR+/HER2- aBC/MBC and PIK3CA mutations while Senior Consultant Pathologist Professor Dr Pathmanathan Rajadurai explained the process of detecting PIK3CA mutations in patients.
Natalia Reoutova, 26 Jan 2021

Results of the registrational phase I/II ARROW trial of pralsetinib, presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, reveal overall response rates (ORRs) of 60 percent in pretreated and treatment-naïve RET-mutated (RETmut) medullary thyroid cancer (MTC) patients.